Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24015360 | 0.93 | ELANE (0.37) | ELANELMNAHSD17B10 | |
| SCHEMBL18685461 | 0.89 | TSHR (0.32) | RIPK1 | |
| SCHEMBL19105258 | 0.78 | TSHR (0.33) | ELANE | |
| SCHEMBL106867 | 0.77 | RIPK1 (0.37) | ELANERIPK1 | |
| SCHEMBL17617204 | 0.74 | DGAT1 (0.38) | ELANELMNAHSD17B10 | |
| SCHEMBL13317330 | 0.74 | DGAT1 (0.38) | ELANELMNAHSD17B10 | |
| SCHEMBL20054906 | 0.73 | ELANE (0.38) | ELANELMNAHSD17B10 | |
| SCHEMBL17424782 | 0.73 | ELANE (0.35) | ELANELMNAHSD17B10RIPK1 | |
| SCHEMBL19105276 | 0.73 | TSHR (0.35) | — | |
| SCHEMBL28343532 | 0.72 | LMNA (0.36) | ELANELMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | ELANE 3185/4885LMNA 3839/4885HSD17B10 4286/4885 |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | TLR3, TLR2, TLR9 | ELANE 3185/4885LMNA 3839/4885HSD17B10 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.